TARS

Tarsus Pharmaceuticals, Inc.

37.06 USD
+0.11 (+0.30%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Tarsus Pharmaceuticals, Inc. stock is up 29.85% since 30 days ago. The next earnings date is May 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 9 March’s closed higher than February. In the last 7 Unusual Options Trades, there were 7 CALLs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
02 Feb 20:13 19 Jul, 2024 30.00 CALL 60 30
26 Feb 15:37 19 Jul, 2024 20.00 CALL 20 2
26 Feb 18:46 15 Mar, 2024 35.00 CALL 675 17
27 Feb 17:40 19 Apr, 2024 17.50 CALL 30 1092
27 Feb 20:47 18 Oct, 2024 45.00 CALL 100 0
27 Feb 20:48 18 Oct, 2024 45.00 CALL 100 0
28 Feb 14:37 19 Apr, 2024 20.00 CALL 15 77

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the. treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.